CA1201988A - Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes - Google Patents

Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes

Info

Publication number
CA1201988A
CA1201988A CA000406449A CA406449A CA1201988A CA 1201988 A CA1201988 A CA 1201988A CA 000406449 A CA000406449 A CA 000406449A CA 406449 A CA406449 A CA 406449A CA 1201988 A CA1201988 A CA 1201988A
Authority
CA
Canada
Prior art keywords
lectin
gra
glyco
cells
related antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000406449A
Other languages
French (fr)
Inventor
Masakazu Adachi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP56156413A external-priority patent/JPS5857318A/en
Priority claimed from JP15641481A external-priority patent/JPS5857321A/en
Priority claimed from JP56158472A external-priority patent/JPS5859922A/en
Priority claimed from JP56158473A external-priority patent/JPS5859923A/en
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of CA1201988A publication Critical patent/CA1201988A/en
Expired legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ABSTRACT OF THE DISCLOSURE
This invention relates to a cancer cell-combatting lympocyte, a process for the production of such lymphocytes, and an anticancer drug containing the lymphocyte as an active ingredient. The lymphocytes have a glyco-related antigen which is derived from the cancer cells. The antigen is a cancer cell membrane component capable of combining with a lectin which can combine with a terminal galactose or a terminal N-acetylgalactosamine and which is isolated from a cancer cell membrane component with the lectin. These new lymphocytes effectively and specifically combat cancer cells and the anticancer agents contain the lymphocytes which use the immune response of the lymphocytes are proven effective.

Description

L9~1~

CANCER CELL-CO~IBATTING LY~IPHOCYTES~ PROCESS
FOR TI~E PRODUCTION THEREOF, AND ANTICANCER
AGENTS CONTAINING SAID LYMPHOCYTES

FIELD OF rHE INVENTION
The present invention relates to cancer cell-combatting lymphocytes (hereinafter referred to as "killer cells") and a process for the production thereof More palticularly it is concerned wi-th killer cells which act specifically on cancer cells having a glycorelated antigen deri~ed from the cancer cells (this antigen is hereinafter lefeTred to as "GRA") and destroy the cancer cells, and a process for the production of said killer cells. Additionally the p~esent invention relates to a novel anticancer agent, more specifically containing the killer cell or GRA as an active ingredient.
BACKGROUND OF THE INVE~TION
1~ It i5 known that immune response effector cells, particularly T lymphocytes playing a main role in cell-medl~ted immune response, cause rejeotion of grafts due to ~oleign cell antigens, but exhibit no appreciable or very limited immuno-inhibition against cancer cells. Thus, the ~O cance-r cells are not destroyed and multiply in vi~o, finally putting the cancer-bearing host to death.

. ~

However, the mechanism responsiole to the recogni-tion of self from not self is not completely clear and various investigations have been made to have insight into the nature of material basis involved in swch system. For example, cell surface markers on mouse leukemia cells or embryonal carcinoma cells using lectins such as Dolichos biflorusagglutinin (DBA) and peanut agglutinin (PNA) as described in Biochem. Biophys.
~es. Comm. 89 (~) 448-455 (1979), Ibid. 96 (4) 1547-1553 (1980), J. Biochem. _ 473-481 (1981) and Cell 18 183-191 September 1979.
However, as far as is known, there have been no appreciable attempts to provide new lymphocytes that can combat cancer cells specifically and also provide anticancer agents utilizing immune response of lymphocytes.
SUMMARY OF THE INVENTION
As a result of extensive studies on the immune response of the host to cancer cells and its application to the treatment of cancer, it has been found that, in a cancer cell specific antigen which is not found in differentiated normal cells, there is GRA which acts as an immunogen for
- 2 .. .. . . " .. ~ .. , , , .. . - .. . .. . .. .. .

the host and have very high immunogencity that cause an immune response specific to the cancer cells. Furthermore, it has been found that when GRA is used to sensitize lympho-cytes, ther~ can be obtained killer cells which act speci-fically on cancer cells containing GRA and if the killercells are administered to the host, they recognize GRA and act on the cancer cells containing GRA~ destroying them, and thus ~hat they exhibit an excellent effect in ~he treatment and prevention of cancer.
Therefore, the present invention provides killer cells in one embodiment thereof.
In another embodiment, the present invention pro-vides a process for the production of killer cells.
In still another embodiment~ the present invention provides an anticancer agent containing a killer cell or GRA
as an active ingredient.
BRIEF DESCRIPTION OF THE DRAWINGS
_ Fig. l is a microphotograph of Daudi cancer cells;
Fig. 2 is a microphotograph lllustrating the forma-tion of plaques by GRA-l-K-T of the cancer cell of Fig. l;
Fig. 3 is a microphotograph of KAIO-III cancer
- 3 , . .... ..... .. ~.t.. , ~z~g~

cells;
Fig. 4 is a microphotograph illustrating the forma-tion of plaques by GRA-l-K-T of the cancer cell of Fig. 3;
Fig. 5 is a microphotograph of BT-I cancer cells;
Fig. 6 is a microphotograph showing -thé formation of plaques by GRA-l-K-T of the cancer cell of Fig. 5;
Fig. 7 is a microphotograph of MKN-45 cancer cells;
Fig. 8 is a microphotograph showing the formation of plaques by GRA-l-K-T of the cancer cell of Fig. 7;
Fig. 9 is a microphotograph of MOLT cancer cells;
Fig. 10 is a microphotograph showing the formation of plaques by GRA-l-K-T of the cancer cell of Fig. 9;
Fig. 11 is a microphotograph of BT-l treated with a mixture of unsensitized human peripheral blood lymphocytes;
Figs. 12 and 13 are each a microphotograph of the cancer cell tissue of cancer-bearing mouce which is adminis-tered with GRA-M-l-K;
Fig. 14 is a microphotograph showing the state of cancer in a cancer-bearing mouse group which is administered with GRA-M-l;
-Fig. lS is a microphotograph showing the state of cancer in a cancer bearing mouse group which is not administer-ed with GRA-M-l;
- 4 Fig. 16 is a microphotograph showing the cancer cell tissue of a cancer-bearing mouse group which is not administer-ed with the GRA-M-l;
Fig. 17 is a microphotograph of the cancer cell tissue of the group which is administered with GRA-M-l;
Fig. 18 shows an SDS gel electrophoresis diagram of GRA using protein staining by C.B.B. method;
Figs. 19 to 21 show SDS gel electrophoresis diagrams of GRA using sugar coloration by PAS method;
Fig. 22 is a schematical illustration of the results of SDS gel electrophoresis diagram of GRA using pro~ein staining by C.B.B. method; and Fig. 23 represents a graph showing tumor growth rate in C3H/HQ mouse transplanted with X5563 immune mouse spleen cells and X5563 cells.
DETAILED DESCRIPTION OF THE INVENTION
.
The killer cells of the invention can be prepared, for example, by a method in which~GRA is used to sensitize lymphocytes.
GRA as used in the above method can be obtained from cancer cells containing GR~ of humans or animals, e.g., cultivated cancer cells, transplanted cancer cells, spon-taneausly-occurring cancer cells, chemical substance or virus-induced cancer cells, and cancer cells derived from operated tissues, by the following procedure
- 5 -Cell membrane components are separated from cancer cells as described above and treated with a lectin which combines specifically with a terminal galactose or a terminal N-acetylgalactosamine, whereby GRA is combined with the lectin and can be easily separated.
Suitable examples of the galactose-binding lectin include peanut lectin, Ricinus communis lectin and Soybean (Glycine max) lectin (see J.B.C., 250, 8518-8523 (1975);
Biochem. Biophys. Res. Comm., 62, 14~ (1975); Z. Immunitaets-forch, 138, 423-433 ~1969); Br. J. Exp. Pathol, 27, 228-236 ~1946); Proc. Nath. Acad. Sci. USA, 75, No. 5, 2215-2219 (1978);
, _ _ _ _ Biochemistry, _, 196-204 (1974); and Carbohydrate Research, 51, 107-118 (1976)). Suitable examples of the N-acetyl-galactosamine-binding lectin include Dolichos bean (Dolichos biflorus) agglutinin, braid orange lectin, Helix pomatia lectin, lima-bean (Phaseolus limensis) lectin, soybean (Glycine max) lectin and Bauhinia bean (Bauhinia purpurea) lectin.
The separation of the cancer cell membrane compo-nents can be achieved by known techniques such as a homogeni-zation method and a solubilization method using a dissolving agent. It is more advantageous to employ a method in which - - \

cancer cells are homogenized in physiological saline or in an appropriate buffer, a portion precipitated is collected by a technique such as centrifugal separation and dissolved in physiological saline or a buffer by the use of a dis-solving agent, and the supernatant portion is separated bya technique such as centrifugal separation. Dissolving agents which can be used include surface active agents which are generally known to be capable of dissolving cell membrane, such as nonionic surface active agents, e.g., TRITON X-100 ~produced by Wako Pure Chemical Industries Ltd.) 3 NP-40 (produced by Shell Co., Ltd.), digitonin, and urea, and anionic surface active agents, e.g., sodium dodecylsulfonate (SDS).
From the thus-obtained cell membrane components can be separated GRA capable of combining with lectin by usual physical chemical or biochemical techniques utilizing the properties of lectin. Examples of such techniques include affinity chromatography utilizing a column carrier containing lectin, an immune precipitation method using GRA
antibody or the like, a dialysis method, a gel filtration method, an electrophoresis method, a physical precipitation method Usillg a sugar protein-precipitating agent, e.g., poly-ethylene glycol and acetone, and a combination thereof.
More pTeferred is affinity chromatography utilizing a column carrie~ containing lectin, and the column carrier can be ~Z4~ ;3~

easily prepared by immobilization of lectin on an insoluble support. Such immobilization of lectin on an insoluble support can be performed by known techniques which are con-ventionally employed in immobilization of biosubstances.
Of these techniques, it is preferred to use a cyan bromide activation polysaccharide method and an immobilization me~hod using N-hydroxysuccimide esters. The cyan bromide activation polysaccharide method is a method in which an insoluble support is treated with cyan bromide, and the activated product thus obtained is subjected to a coupling reaction with lectin under mild conditions to immobilize lectin. In treating the insoluble support with cyan bromide, for example, basic compounds such as sodium hydroxide and sodium hydrogen-carbonate are used to adjust the pH to from 7 5 to 12, and the support is treated in a solvent such as water, aceto-nitrile, or a buffer maintained at pH 7.5 to 12, for example, a 0.1 M sodium hydrogencarbonate buffer (pH about 8.7) and 0.01 M phosphate buffer (pH about 7.7), at room temperature for about 1 ~o 12 minutes. Usually the amount of the cyan bromide used is preferred to be equal to that of the insoluble support.
Any known insoluble support which is o low non-specific adsorption to all biosubstances, has high porosity, contains a functional group capable of immobilizing bio-substances under mild conditions~ and is chemically and -.

1 physically sufficiently stable can be used in the invention.
Insoluble supports which can be used include a support made of cellulose, e.g., aminoethyl cellulose, carboxy-methyl cellulose, bromoacetyl cellulose, and p-anilino cellulose, a support of cross-linked dextranr e.g., SEPHADEX* and CM-SEPHADEX* ~produced by Farmacia Corp.~, and a support of agarose, e.g., SEPHAROSE* 2B, SEPHAROSE*
4B, and SEPHAROSE* 6B (producecL by Farmacia Corp.).
In the coupling reaction of the cyan bromide-activated support as obtained above with lectin, the cyan bromide-activated support is used in an amount from 30 to 80 times the lectin, and they are reacted in an appropri-ate solvent such as a 0.1 mol/Q aqueous solution of sodium hydrogencarbonate ~containing 0.5 mol/Q of sodium chloride;
pH: 8.4) at a temperature of from O to 40C, preferably from 2 to 8C for a period of from about 10 to 20 hours.
In this way, there can be prepared a carrier for affinity chromatography containing lectin.
By chromatography using the lectin-containing carrier as prepared above, the desired GRA combines with the lectin contained in the carrier and its trapped in the column. Subsequently, substances capable of combin-ing with e.g., *Trade Marks ~z~

lectin can be passed through the column to perform an exchange reaction, or alternatively an adsorption separator (eluting solution), e.g., a high concentration salt, an aqueous solu-tion of potassium thiocyanate, and a nitrate buffer, is passed through the column to dissociate and obtain the desired GRA.
In the exchange reaction, examples of the substances capable of combining with lectin when a carrier :For affinity chromatography containing galactose-binding lectin is used include those which can combine with a terminal galactose-combining lectin, e.g., galactose, disaccharides containinga terminal galactose and oligosaccharides containing a termi-nal galactose, and examples of the substances capable of combining with lectin when a carrier for affinity chromato-graphy containing N-acetylgalactosamine-binding lectin is used include those which can combine with a terminal N-acetyl-galactosamine-combining lectin, e.g., N-acetylgalactosamine, disaccharides containing a terminal N-acetylgalactosamine and oligosaccharides containing a terminal N-acetylgalactosamine.
The thus-obtained GRA contains glycoprotein contain-ing a galactose and/or N-acetylgalactosamine terminus, glyco-lipid and/or saccharide.

9~

The ~RA thus prepared can be lyophilized, if desired and further purified using ordinary separation techniques. For example, those GRA preparations isolated with a galactose-binding lectin can be subjected to a separation method using a N-acetylgalactosamine-combining lectin, and those isolated with a N-acetylgalactosamine-combining lectin can be treated by a separation method using a galactose-binding lectin.
Lymphocytes as used herein are not cri~ical~ and any lymphocytes of normal or cancer-bearing human being or animals can be used. Examples include those lymphocytes derived from peripheral blood, bone marrow, lymph node, spleen, tonsils, and thymus. These lymphocytes are isolated by physical or chemical techniques, a surface membrane method, or the like.
The sensitization of lymphocytes with GRA is per-formed by cultivating the lymphocytes on a culture medium containing GRA for a period of from 1 to 10 days 7 preferably from 2 to 7 days.
As culture media for use in the sensitization of lymphoc~tes, there can be used various common nutrient media which are conventionally used in such cell cultivation.
PreferTed examples include a RPMI 1640 medium, an Eagle MEI~
cul~ure, etc. with human serum, calf fetus serum ~FCS), calf serum, horse serum or the li~e added thereto. The amount of GRA being added to the culture is usually from 1 to 1,000 ng/ml and preferably from 1 to 500 ng/ml, as calculated as an amount of sugar, per lxlO6/ml lymphocyte.
The cultivation is performed by the common method, for example, at a pH of about 7.2 and a temperature of about 37C.
The killer cells of the invention as prepared above are substantially normal lymphocytes and have a GRA-specific cell-combatting activity For example, GRA-l-~T~ which is one of the killer cells of the invention, has properties common to human peripheral blood T cells and shows ~ cell-combatting activity which is specific to cancer cells containing GRA, which is shown in the example as des-clibed heleinater.
Typical examples of the novel killer cells of the 1~ invention aTe GRA-l-KT and GRA-M-l which are prepared in the examples as described hereinafter. All the killer cells are available from the appli~nt and their deposition in ATCC has been requested.
The killer cells of the invention can be multiplied unlimitedly on the above-d~scribed culture medium containing a T cell growth factor~TCGF, IL-2 ). In this case, selective cultivation of cloning of ~he ~iller cell may be performed by the conven-ti~nal ~ltra-dilution method These killer cells can be store~ st~ly ov~r a long period o time, for example~ in 2~ liquid ni~rogen ~2~

The GRA can be used singly as an active ingredient and additionally, can be used in combination with other antibacterial agents and cancer-inhibiting agents. Cancer-inhibiting agents containing the GRA of the invention as an active ingredient may be in any form as long as they are in the condition that the GRA is contained in effective amounts Usually the agent is administered intravenously, subcutaneously, intradermally or intramuscularly as a solution, a suspension or as an emulsion. In addition, it may be provided as a dry product which can be made liquid by the addition of a suitable carrier prior to the use thereof. These liquid agent may contain a suspending agent, e.g., methyl cellulose, an emulsifying agent, e.g., lecithin, preservatives, e.g., methyl-p-hydroxy benzoate, a stabilizer which does not exert as such adverse lS influences on the immuni~ing function of humans or animals, - a buffer, and the like.
Aqueous carriers which can be used include physio-logocal saline, and non-aqueous carriers which can be~used include vegetable oil, e.g.~, sesame oil, mineral oil, e.~., paraffin, animal oil, e~g., squallene, and propylene glycol.
In addltion, for the purpose of immunological enhancement, . ._.. .. ~

~2~g~

appropriate adjuvants may be incorporated. Adjuvants which can be used include Freund's complete adjuvants, saponin for animals, and aluminum hydroxide for humans.
The anticancer agent of the invention can be administered once or repeatedly over a long period of time to a cancer patient for the treatment of cancer, or can be administered to one who is liable to suffer from cancer for the preven~ion of cancer.
Since LD50 (mouce, intraperitoneal) of GRA is at least 500 mg/kg as calculated as an amount of sugar9 the anticancer agen~ of the invention is of low toxicity and, therefore, it can be administered within a wide range of dosage. Although the concentration of GRA in the anticancer agent of the invention is not critical, it is usually pre-ferred to be from 0.001 to 100 ~g/ml as calculated as an amount of sugar. With regard to the dose of the anticancer agent, it is usually preferred that the agen~ is administered in an amount of 0.001 to 1,000 ~g/kg/day, at the same time or in several portions, although it varies depending on the extent of disease,and the age and sex of the patient.
The thus-prepared anticancer agent containing the killer cell as an active ingredient is preferably used as an injectable solution in combination with carriers which are used -in the preparation of such blood medicines.
Carriers as used herein are no~ critical, but carriers . ..

~0~

having a tonicity equal to that of blood are preferred. In particular, physiological saline is preferred. In the preparation of the agen~, it is pre~erred that the killer cell is sufficiently washed with physiological saline or the like to remove the above-described culture medium and, there-after, it is floated in a carrier.
The concentration of the killer cell in the agent is not limited specifically, but it is preferably from 105 to 10 per milliliter. When the killer cell is adminstered intraperitoneally in a dose of 108 per mouce, no toxity is observed. Although the dose of the anticancer agent of the invention varies depending on the degree of disease, and the age and sex of the patient, it is usually preferred that the - agent is administered in a dose of 105 to 1012/kg/day, in lS one pOTtiOn or in divided portions.
The following example, reference examples, experi-ment examples, and comparative examples are given to illust-rate the invention in greater detail although the invention is not limited there*o.

Locality of GRA
~l)-A Preparation of FITC-labelled Lectin ~PNA-FITC) Ten milligrams of peanut lectin ~PNA, produced by EY Co.) was dissolved in 2 ml o-E a 0.01 M phosphate buffer containing 0.85% NaCl CpH=7.2). In 1 ml of a 0.5 M hydrogen-~z~

carbonate buffer (pH=9.0) was dissolved 2 mg of FITC ~pro-duced by Sigma Laboratories Inc.), and a 0.5 ml portion of the resulting solution was added to the above prepared PNA
buffer. The mixture was then stirred at room temperature for 2 hours and, thereafter, it was separated on Sephadex G25 (10 mm x 300 mm, produced by Farmacia Corp.). The initial peak was collected. FITC/PNA ratio=lØ
(l)-B Preparation of FITC-Labelled Lectin (DBA-FITC) In the same manner as in (l)-A above DBA-FITC was obtained using DBA produced by EY Co. FITC/DBA ratio=0.9.
(l)-C Soybean agglutinin FITC (FITC-SBA) is available from EY Co. FITC/SBA ratio=1.4.
~2) Locality of GRA in Various Cancer Cells ~a) Human cultured cancer cells ~lx106) were washed three times with a 0.05 M tris hydrochloric acid buffer containing 0.85% NaCl ~pH=7.2) by a centrifugal procedure and then 100 ~1 o-f PNA-FITC, DBA-FITC or SBA-FITC ~200 ~g/ml) as prepared in ~l) above was added thereto. The resulting mix-ture was allowed to stand a~ room temperature for 30 minutes to cause them to react. After the reaction was completed, the reaction mixture was washed three times with a 0.01 M
phosphate buffer containing 0.85% NaCl ~pH=7.2) and, there-after, the cells were placed on a glass plate and examined under a fluorescent microscope.
Mouse X5563 and mouse MH134 were treated and .... - ,,, ''' ! '. : : " ' ' e~amined in the same manner as above.
The results are shown in Table 1. The cancer cells used are all known and have been obtained from First Pathology Laboratories, Medical Department of Niigata University.
Table 1 Positive Ratio of Cancer Cells GRA _ (%) PNA DBA SBA
Raji (Burkitt lymphoma) 98.3 1.4 Dauji ~Burkitt lymphoma) 93.1 5.2 BT-l (Burkitt lymphoma) 50.1 0 P-12 (T-cell lymphoma) 44.3 6.7 MOLT ~T-cell leukemia) 0.6 4.8 Fujimaki (B-cell lymphoma) 19.1 5.3 Oda ~IgD myeloma) 0.6 10.0 QG-56 (lung cancer, squamous) 70.4 2.0 PC-l (lung cancer, squamous) 78.4 0.4 PC-3 (lung cancer, adenocarcinoma) 77.1 0 QG-90 ~lung cancer, small cell)68.0 0 PC-13 (lung cancer, large cell)17.0 0 MK-2 (stomach cancer, poor diferentiation) 63.7 0.1 KATO-III ~stomach cancer, signe~
ring cancer) 57 3 0 MKN-45 (stomach cancer, poor differentiatlon) 1.0 40.3 MKN-l (stomach cancer, adenocarcinoma-squamous) 4.6 0.4 Positive Ratio of Cancer Cells GRA (%) -PNA DBA SBA
MKN-28 ~stomach cancer) 0.4 0.1 MKN-74 (stomach cancer) 0.5 0 MGH-Ul (urinary bladder cancer) 37.4 0 KU-2 ~urinary bladder cancer) - 4.5 21.4 T-24 (urinary bladder cancer) 14.6 0 NBT-2 (urinary bladder cancer) 13.1 1.0 NRC-12 (renal cancer) 23.9 0 KU-l (renal cancer) 3.3 0.6 Kuramochi (ovarian cancer) 80.0 0 NB-l ~neuroblastoma) 50.9 1.7 YT-nu tneuroblastoma) 3.6 0.5 TGW-nu-l ~neuroblastoma) 4.1 0 TGW-nu-ll ~neuroblastoma) 2.0 1.0 GOTO (neuroblastoma) 0.5 0 ITO (embryonal carcinoma) 96.9 12.3 NEC-8 ~embryonal carcinoma) 44.6 0 SCH tchoriocarcinoma, stomach) 14.6 3.1 GCH ~chriocarcinoma, u*erus) 5.4 0 YN-l (rhabdomyosarcoma) 5.7 1.7 Mouse X5563 ~plasmacytoma) 92.0 0 90.6 Mouse MH134 ~hepatoma) 18.6 0 6.4 .. , . . - ~;
- ^ ... . ... . . .

(b) The ~alignant tissues from cancer patients were passed through a stainless steel mesh (#150) to make single cell suspension. After wasiling twice with 0.01M Tris-~lCl buffer (pH=7.4~ containing 2mM CaC12, 2mM MgC12 and 0.85%
NaCl~ 5x105 cells were resuspended in 100 ~1 of the buffer.
One hundred ~1 of FITC-PNA or FITC-DBA (200 ~g/ml) was added to the cell suspension and the mixture was incubated at room temperature for 20 minutes. After washing three times with cold PBS, the cell were observed under a fluorescene micro-scope.
The results are shown in Table 2. The malignant tissues from cancer patients have been obtained from Kansai Medical University.
Table 2 GRA
No. Cancer Patient Tissue PNA DBA
1 Stomach cancer + +
2 Stomach cancer + +
3 Stomach cancer - -4 Stomach cancer +
Stomach cancer + +
6 Stomach cancer +
7 Breast cancer ~ - -
8 Breast cancer +
9 Breast cancer +
Breast cancer +

GRA
No. Cancer Pa~ient Tissue PNA DBA
11 Colon cancer ~ +
12 Colon cancer -13 Esophagus cancer ~ -14 Hepatoma - +
Note: Symbol "+" indicates GRA is expressed on the cell surface.
Symbol "-" indica-tes GRA is not expressed on the ~ell surface.

Preparation o-f GRA
(l)-A Preparation of Immobilized Lectin ~PNA-Sepharose) Three grams of CNBr-activated Sepharose 4B (pro-duced by Farmacla Corp.) was fully washed with 1 mM HCl and suspended in 200 ml of 0.1 M sodium hydrogencarbonate ~pH=
8.5). Then, 5 ml of a 0.01 M phosphate buffer ~pH=8.5) containing 20 mg of PNA was added, and they were reacted at 25C for 2 hours while sometimes stirring to prepare PNA-Sepharose.
~l)-B In the same manner as in ~l)-A above except that DBA
is used instead of PNA, DBA-Sepharose was obtained.
~2) Prepara-tion of GRA
~ a) BT-l (Burkitt lymphoma) cells (1.3x108) were washed three times with physiological saline, and 30 ml of a 0.01 M
tris hydrochloric acid buffer (pH=7.4) containing 2% of , . .

1 "TRITON* X-100" (produced by Wako Pure Chemical Industries Ltd.), 0.85% of NaCl, 2 m~l of CaC12, and 2 mM of MgC12 was added thereto. The mixture was stirred at 4C Eor 15 minutes and then was subjected -to ultracentriEugal separ-ation at a rate of 100,000 x g. O~ 28 ml of the thus-obtained supernatent liquid, a 14 ml p~rtion was passed through a column (diameter 0.5, length 1 cm) for affinity chromatography, packed with PNA-agarose beads (produced by Maruzen Co., Ltd.) which had been equilibrated by a tris hydrochloric acid buffer (pH-7.4) containing 0.1%
TRITO~* X-100, 0.85% NaCl, 2 mM CaC12, and 2 mM MgC12.
After being washed with the same buEfer as used above, it was eluted with a 0.01 M -tris hydrochloric acid bu~fer (pH--7.4) containing 0.1 ~ lactose, 0.85~ NaCl, 2 mM CaC12, 2 mM MgC12, and 0.1% ~RITON* X-100. The thus-eluted portion was dialyzed with a 0.01 M tris hydrochlorie acid buffer containing 0.85% NaCl, 2 mM MgC12, and 2 mM
CaC12 for 48 hours to obtain 17 ml of a GRA solution.
With the GRA solution, the amount of protein and the amount of sugar were measured by the Folin-Lowry method and the phenol-sulfuric acid method, respectively, and they were found to be 544 ~g and 120 ~g, respeetively, This is hereinafter referred to as "GRA-l".
~b) C3H/He Mouse mammary tumor (MMT) cells (lx101~ were washed three times with physiologieal saline, and 20 ml of a 0.01 ~ tris hydrochlorie acid buffer (pH-7.4) c~ntaining *Trade Mark - 21 2% TRITON X-100, 0.85~ NaCl, 2 m~l CaC12, and 2 mM MgC12 was added thereto. The mixture was stirred at 4C for 30 minutes.
Subsequently the mixture was subjected to ultracentrifugal separation at a rate of 100,000 x g for 2 hours, and the supernatant liquid was dialyzed over-night with a 0.1 M tris hydrochloric acid buffer (pll=7.4) containing 0.85Po NaCl, 2 mM CaC12, and 2 mM MgC12. The thus-dialyzed liquid was concentrated to 3 ml, and a 1 ml portion was then passed through a column ~diame-ter0.5 ~l, length 2 cm) for affinity chromatography, packed with the same PNA Sepharose as used above which had been-equilibrated with a tris hydrochloric acid buffer ~pH=7.4) containing 0.005% TRITON X-100, 0.85%
NaCl 3 2 mM CaC12, and 2 mM MgC12. After being fully washed with the same buffer as used above, it was eluted with a 0.01 M tris hydrochloric acid buffer ~pH=7.4~ containing 0.1 M lac-tose, 0.85% NaCl, 2 mM CaC12, 2 mM MgC12, and 0.005%
TRITON X-100, and the thus-eluted portion was dialyzed for 4~ hours with a 0.01 M tris hydrochloric acid buffer ~pH=7.4) containing 0.85% NaCl, 2 mM CaC12 and 2 mM MgC12 to obtain 2 ml of a GRA solution. With the GRA solution thus obtained, the amount of protein and the amount of sugar were 156 ~g and 94 ~g~ respectively. This is hereinafter referred to as 1tGRA-M-l"

(c) Approximately 120 g (wet weight) of KATO-III was a homogeni7ed in 100 ml of PBS by a Waring blender. After `
centrifugation at 100,000 g for 1 hour, the pellet was dis-solved with a in 100 ml of 2% TRITON X-100 in 0.01 M Tris-HCl buffer (pH=7.6) containing 0.15 M NaCl. The supernatantcollected by centrifugation at 100,000 g for 1 hour and applied to a column of PNA-Sepharose 4B (0.8x15 cm) equili-brated with 0.015% TRITON X-100 in 0.01 M Tris-HCl (pH=7.6) containing 0.15 M NaCl. After washing with 50 ml of the buffer, the GRA were eluted with the buffer containing 0.1 M lactose. The eluted GRA dialysed against 0.85~ NaCl, concantrated by Sephadex Pharmacia Co. and stocked at -20C
before use.
The amounts of protein and sugar determined in the same manner as in (a) above were found to be 2.0 mg and 0.8 mg, respectively. This is hereinafter referred to as "GRA-2"
(d) In the s~me manner as in (c) above~ the ~ollowing GRA samples were obtained.

Table 3 GRA
GRA Material Protein Sugar Sample SourceAmount Content Content ~g~ mg) (mg) GRA-3 BT-l 33 0.5 0.09 GRA-4 Breast Ca. 5 0.24 0.5 ~excised) GRA-5 QG-56 24 0.6 0.38 GRA-6 QG-90 26 1.0 0.54 GRA-7 Raji 29 0.78 0.45 GRA-M-2 MMT 200 11.3 28.4 GRA-M-3 LLC 14.4 0.06 0.07 GRA-M-4 MH-134 85 0.65 0.35 GRA-M-5 X-5563 25 0.56 0.23 ~e) In the same manner as in ~c) above e~cept that MKN-45 ~about 2g g) was used instead of Kato-III and DBA-Sepharose obtained in ~l)-B above was used instead of PNA-Sepharose 4B
and elution was carried out with N-acetylgalactosamine, a GRA preparation having a protein content of 0.03 mg and a sugar content of 0.01 mg was obtained. This is hereinafter referred to as "GRA-8".
~f) GRA-3 prepared in ~d) above ~5 mQ) was charged in DBA-Sepharose column and eluted with Tris-HCQ buffer (0.015%
Triton X-100, 2 mM MgCQ2 CaCQ2, O.85% NaCQ) to obtain 4 mQ
fractions Nos. 1-12. Fractions Nos. 1-3 are termed "GRA-3-A"
and Nos. 4-12 "GRA-3-B". Then, the column was eluted with the same buffer but containing 0.1 M N-acetylgalactosamine 9~

to obtain fractions, which is termed "GRA-3-C".
~g) SDS Gel Electrophoresis Each of the GRA preparations according to the above procedures was subjected to electrophoresis according to the method described in Fairbanks et al: Biochemistry vol. 10 p.2606, 1971.
The results obtained are shown in Figs. 18 to 22.
In Figs. 18-19~ numerals 1 to 5 indicate the following.
1 --- standard; 2 --- GRA-~1-3; 3 --- GRA-7;
4 --- GRA-l; and 5 --- GRA-2 In Fig. 20 numerals 1 to 4 indicate the following.
1 --- standard; 2 --- GRA-M-2; 3 --- GRA-6;

In Fig. 21 numerals 1 to 3 indicate the following.
1 --- GRA-M-4; 2 --- GRA-M-5; 3 --- standard In Fig. 22 numerals 1 to 4 indicate the following.
1 --- GRA-3; 2 --- GRA-3-A, 3 --- GRA-3-B;

Fig. I8 shows the state of GRA s~bjected to protein staining reaction according to C.B.B. method ~Fairbanks et al: Biochemistry vol. 10 p.2606, 1971).
Figs. 19-21 shows the state of GRA subjected to sugar coIor reaction according to PAS method (R.M. Zacharius et al: nal. Biochem. vol. 30 p.l48 ~1962)).
Fig. 22 shows schematical illustration of the results of staining according to the C.B.B. method described above.

For the standards substances listed belol~ from Biorad Lab. Calif. U.S.A. were used.
200 K dalton; myosin 116 " ; ~-galactosidase 92.5 " ; phosphorylase 66.2 " ; BSA
45 " ; ovalbumin 21.5 " ; soybean trypsin inhibitor Preparation of TCGF
(a) The spleen (4 kg) of Japanese monkey (obtained from Japan Plymates Co., Ltd.) was excised and washed twice with a RPMI-1640 culture medium ~produced by Flow Laboratory Co.
Ltd.). Cells were filtered by the use of Mesh ~produced by Milipore Inc., 150 mesh) and were subjected to a specific gravity centrifugal method (specific gravity, 1.076) to obtain 2 liters of 2xlO9/ml of lymphocytes. The thus-obtained lymphocytes were washed three times with a RPMI-1640 - culture medium~ and the lymp~hocyte number was adjusted to 5x107 per millillter by the use of the same medium as used above, containing 10% FCS. It was then allowed to stand in a carbon dioxide fermentation apparatus at 37C for 1 hour.

~2ai1~

The supernatant lymphocytes were recovered and the lymphocyte number was adjusted to lx106 per milliliter by the use of the same culture medium as used above, containing 1% FCS. Sub-sequently 1 ~g/ml of indomethacin ~produced by Sigma Laboratories, Inc.) and 0.2% PHA-P ~produced by Difco Co.) were added, and they were cultured in a carbon dioxide gas fermentation apparatus at 37C for 48 hours. A centrifugal separation procedure (3,000 rpm) was applied for 10 minutes, and the resul~ing supernatan-~ liquid was recovered and sterilyzed by filtering with a Millipore filter ~produced by Millipore Inc., 0.2 ~m) to obtain 2 liters of ~CGF.
~ b) The source of TCGF was the supernatant of mix-cultured peripheral blood lymphocytes of 10 healthy donors.
Non-adherent lymphocytes prepared from C.F ~Conray. Ficol ~Japan Immunoresearch Co.)) separated lymphocytes by adsorp-tion on plastic surface at 37C for 1 hour were suspended in RPMI 1640 medium containing 1% FCS ~l.Sx106 cells/ml) and incubated with 0.2~ PHA-P, indomethacin (1 ~g/ml) and human ~-cell line ~T-l) ~1 sx105 cells/ml) pretreated with mito-mycin C (50 ~g/ml). After 48 hours, the culture supernatan~was harvested and used as TCGF source. ~H. Inoue et al, Scand. J. Immunol. 12 p.149-154 (1980)) 9~

REFERENGE EXA~IPLE 4 Preparation of Lymphocytes (1) Human Peripheral Blood Lymphocytes Blood ~50 ml) obtained ~rom a healhty adult or various cancer patients by heparinization was subjected to centrifugal separa~ion by ~he use of Ficol Pack ~produced by Farmacia Japan Co., Ltd.) to obtain 5x107 of peripheral blood lymphocytes.
~2) Mouce Spleen Lymphocytes The spleen of a C3H/He mouce ~male, 6w) was excised and washed twice with a RPMI-16~0 culture medium. The spleen was then loosened by a syringe needle and passed through a stainless steel screen (100 mesh) to remove large pieces.
The thus-filtered cells were washed twice with the same culture medium as used above and was subjected to centrifugal separation at a rate of 1200 rpm for 10 minutes to obtain 4xlO o spleen lymphocytes.

-GRA-l (amount of protein: 40 ~g/ml; amount of sugar: 7.5 ~g/ml) as obtained in Reference Example 2 ~2)-~a)) was diluted to 1,000 times the original volume with aRPMI-1640 culture medium containing 15 ~ FCS to prepare a sensitization culture medium.
Human periphe~al blood lymphocytes ~5X106/5 ml) as obtained in Reference Example 4 (~1)) was added to 5 ml o ~he sensitization culture medium as prepared above which 9~

was placed on a laboratory dish, and cul~ivated at 37C for 2 days They were further cultivated on the RP~ 1640 cul-ture medium containing 20% TCGF and 15% FCS, as obtained in Reference Example 3, for additional five days to obtain 20 ml of a killer cell solution containing 1x106 killer cells per milliliter. This is hereinafter referred to as "GRA-l-K-T".

The mouce spleen lymphocytes as obtained in Refer-ence Example 4 (~2)) were adjusted to a number of 5xlO6/ml by the use of a RPMI-1640 culture medium containing 15% FCS.
Then, GRA-M-l as obtained in Reference Example 2 ~(2)-~b)) was added ~o that the final amounts of protein and sugar were 1.5 ~g/ml and 0.9 ~g/ml, respectively A 5 ml portion I5 of the resulting mixture was cultivated on a laboratory dish (60 mm x 15 mm, produced by Falcon Co.) at 37C for two days.
The formation of cloning was observed. The portion was fur-ther cultivated Oll a RPMI-1640 culture medium having 15% FCS
containing 20% by volume of TCG~ ~produced by Japan Immuno Research Laboratories Co., Ltd.) for additional 4 days to obtain 50 ml of a killer cell solution containing 1x106 killer cells per milliliter. This is hereinafter referred to as "GRA-M-l-K-T".

Peripheral blood lymphocytes (5x106) of healthy donor was incubated in RPMI-1640 medium containing 50 ng/mQ (protein content) of GRA-2 and 15% FCS at 37C. On day 2 the human TCGF described above was added to the medium until the con-centration reached Z0% and incubation was continued for fur-ther 3 days ~o obtain killer cells. This is hereinafter referred to as "GRA-2-K-T".

Killer cell preparations GRA-8-K-T, GRA-3-A-~-T and GRA-3-C-K-T were prepared in the same manner as in EXAMPLE 1 using GRA-8, GRA-3-A and GRA-3-C, respectively (protein content: 50 ng/mQ) and the TCGF obtained in REFERENCE EXAMPLE
3-~b).

C3H/He mice ~female; 8 weeks) was implanted intradermally with X5563 cells ~106) of the same strain and after 7 days the tumor was excised surgically. After another 7 days X5563 cells ~105) o the same strain was inoculated~
and mice resistant to inocula~ion were named immune mouse.
The spleen cells of the immune mice and C3H/He normal mice were prepared according to commonly used method.
Each lot of spleen cells ~5xl06/well) was sensitized with 40 ng/mQ (protein content~ of GRA-M-S in RPMI-1640 medium containing 15% FCS for 5 days to obtain killer cells.
- Killer cell preparation obtained from normal spleen cells ~ 30 -is hereinaf-ter referred to "GRA-M-5-K-T-l" and that obtained from immune spleen cells is hereinafter referred to "GRA-M-5-K-T-2".

Human peripheral blood lymphocytes ~5x106) were incubated in S mQ of RPMI-1640 medium containing 50 ng/mQ (protein content) of GRA-l at 37C for 2 days. On day 3, the lympho-cytes were transferred to RPMI-1640 medium containing 10%
serum from the donor of the lymphocytes and 0 to 100 ng/mQ
~protein content) of GRA-l and incubation was continued for further 5 days to obtain killer cell preparations shown in Table 4 below.
Table 4 GRA Concentration ~n~/mQ) 15Initial Day Day 3 Killer Cell 0 GRA-l-K-T-l 1.6 GRA-l-K-T-2 3.2 GRA-l-K-T-3 6 GRA-l-K-T-4 12.5 GRA-l-K-T-5 GRA-l-K-T-6 GRA-l-K-T-7 100 GRA-l-K-T-8 (a) Peripheral blood lymphocy~es ~PBL) from various cancer - patients after operation were sensitized with GRA-3 to obtain killer cell perparations. PBL (5x106) from the patients were incubated in RP~ 1640 medium containing 50 ng/mQ (protein content) of GRA-3 for 2 days and then in RP~II-1640 medium containing 20% TCGF and 15% FCS for further 5 days to obtain killer cells shown in Table 5.
Table 5 Peripheral Blood Lymphocytes Days after Cancer P-GRA D-GRA Operation Killer Cell Gastric ca. ~ -~ 14 GRA-3-K-T-l " + + 35 GRA-3-K-T-2 Breast ca. ~ - 21 GRA-3~K-T~3 " ~ - 7 GRA-3-K-T-4 " + - 35 GRA-3-K-T-5 Gastric ca. + - 21 GRA-3-K-T-6 In the above table, P-GRA and D-GRA indicate locality of GRA expressed on the malignant tissue (excised by opera-tion) from the cancer patients from whom PBL was collected as determined in the same manner as in REFERENCE EXA~PLE 1, 2-~b). P-GRA and D-GRA are results obtained using ~ITC-PNA
and FITC-DBA9 respectively, The days after operation indicate the timing when PBL was collected after the operation.
tb) PBL (5x106) collected from breast cancer patients after 21 days from the operation was incubated in RPMI-1640 medium containing 50 ng/mQ (protein content) of GRA-3 and 10% serum from tlle patient for 7 days to sensitize PBL and obtain killer cell preparation. This is hereinafter referred to "GRA-3-K-T-7".

EXA~IPLE 8 GRA l-K-T (108) as obtained in Example 1 was dis-solved in 10 ml of physiological saline to prepare an injec-table solution.

(i) GRA-M-l as obtained in Reference Example 2 ((2)-(b)) was diluted with physiological saline so that the amounts of sugar and protein be 1 0 ~g/ml and 1.6 ~g/ml, respectively, to thereby prepare an anticancer agen~ No. 1.
~ii) A tumor lump of C3H/He spontaneously occurring breast cancer was sterilely cut to 5 mm cube clump and transplanted to under the back skin of each o ten C3H/He mice of the same strain as above (7-week-age, males). Seven days after the transplantation, the fixation and multiplication of the tumor were confirmed. To five o the mice were each administered subcutaneously the anticancer No. 1 as prepared in (i) above in a dosage of 300 ~l per day at two day intervals. The remaining five mice were used as untreated controls. Ten days after the first administra~ion~ the tumor was excised by ope-ration~ and the mean weigh~ was measuredO At the same time, pathohistological examination was performed.
Tumor Yolume:
Adminstered group 22.3 mm3 (Fig. 14) Control 162.7 mm3 (Fig. 15) This means that there was a 86.3% reduc~ion in the tumor.
Pathohistological Examination:
~z 7 - Ja -9~

In the control group (Fig.16), birds' nest bodies of cancer were formed, the type o:E tissue was like medullary canalicular cancer and the mul~ip:Lication of tumor cells was observed all over the tissue. On the other hand, in the agent administered group ~Fig.17), the cancer cells caused liquefaction necrosis at the sites where the cancer cells were formed, and calcification and fibrosis occurred, leaving only a very limited amount of cancer cells. Thus, -the anti-tumor proper~ies of the anticancer agent of the invention were observed.
T~ST EX~VIPLE 1 GRA-l-K-T (1 ~1~ as obtained in Example 1 was placed on a microplate (produced by Falcon Corp.) and was allowed to stand at room temperature for 15 minutes. Then, 4 ~1 of FCS (produced by Falcon Corp.) was added and the mixture was allowed to stand at room temperature for 30 minutes. Neuraminidase-treated sheep red blood cells (SRBCN) adjusted in number to lx109 per milliliter and 5 ~1 of a 0.01 M phosphate bu~er (pH=7.2) ~ith 0.~5% NaCl added were added, and the plate was subjec~ed ~o a centrifugal separa-tion procedure at a rate of 600 rpm for 5 minutes. The plate was then reversed, and unreacted SRBCN was rcmoved. A dye-ing solution (Brilliant Cresyl Blue, produced by Merck ~ Co ) was added ~o dye the lymphocytes, and rosette-forming posi-tivity was examined. As a result, it has been found that at least 98% exhibits rosette-forrning positivity (T-cells.) TEST EXA~IPLE 2 -Specific Cancer Cell-Killin~ ActivitY
~a) Of the cells shown in Table 1, the following five cell strains having different GRA positivity ratios were used as targe-t human cancer cells.
Targe-t Cancer Cells:
- Mo. 1 BT-l (Burkitt lymphoma) No. 2 Daudi (Burkitt lymphoma) No. 3 KATO-III (stomach cancer) No. 4 MKN-45 (stomach cancer) No. 5 MOLT ~T cell leukemia) On a microplate ~produced by Falcon Corp.) were laminated 5x104 per well of target cancer cells by a centri-fugal proceduTe at a rate of 800 rpm for 5 minutes. Then, 4x10 per well of GRA-l-K-T as obtained in Example 1 was gently added and incubated for 1 hour.
The killing activity was determined according to the degree of plaques-formation, and was rated as follows:
~+ Killing activity is significantly observed.
-~ ICilling activity is observed.
Killing activity is slightly observed.
- Killing activity is not observed.
In a control group~ there were used unsensitized human peripheral blood lymphocytes which had been prepared in the same manner as in Example 1 except that GRA was not used. The results are shown in Table 6.
It is apparent from Table 6 that the killer T cells produced by the process of the invention have strong GRA-specific cytotoxic activity.
Table 6 _._ Target Cancer GRA Positivity Determination of Cell Ratio ~%) Plaaue-Formation GRA-l-IC-T Daudi (Fig. 1) 93.1 ~-~ (Fig. 2) Group KATO-III (Fig. 3)57.3 + (Fig. 4) BT-l (Fig. 5) 50.1 ++ (Fig. 6) MKN-45 ~Fig. 7) 1.0 + (Fig. 8) MOLT (Fig, 9) 0.6 (Fig. 10) Control ~T-l 50.1 - (Fig. 11) Group (b) The same -~arge~ cancer cells as used in (a) above (3.2x106) were mixed with 8x105 GRA-l-K-T (cell ratio: 5/1) and the resulting cell mixture (total number: 4x106) was cultivated on a RPMI-1640 medium containiJlg 15% FCS. After one hour, the number of remaining cells was counted and the % cytotoxicity was calculated by the following equation.
number of cells after % Cytotoxicity = (1 ~ (number of cells before) x 100) cultivation (4x106) The -results are shown in Table 7 9~3 Table 7 Number of Cells Before Culti- After Cul~i-Target Cell vation vation _ % Cytotoxicity Daudi 4X106 2.9x106 28 KATO-III 4X106 3.7x106 7.5 BT-l 4xlo6 3,2x106 20 MKN-45 4X106 3.9x106 2,5 MOLT 4X106 4.2x106 -5 ~c) The procedure of (b) above was repeated with the exception that the mixing ratio of GRA-l-K-T to target cancer cell was changed to 5/3. The results are shown in Table 8.
Table ~
Number of Cells Before Culti- After Culti-Target Cell vation _ vation ~ Cytotoxicity Daudi 4xlo6 3.6x105 91 KATO-III 4xlo6 3~6X106 24 BT-l 4xlq6 1.4x106 65 M~N-45 4X106 3.7x10 7.2 MOLT 4X106 4.1x106 -3 In the above test it is observed that GRA-l-K-T shows a high binding activity to Daudi, ICATO-III and BT-l but only a low binding activity to MKN-45 and MOLT.

C3H/He spontaneously-occurring breast cancer-bearing mice were administeTed subcutaneously by GRA-M-l-K-T as obtained in Example 2 at a dosage of 3x106/0.3 ml/mouse three times per week every other day. After ten days, the focus was taken out and examined.
As shown in Fig. 129 the infiltration of lymphocytes into cancer cells occurred, and the breakage of the tumor area -was observed. Also, from Fig. 13, it has been observed that the calcification of the tumor area occurred, and thus it can beseen that the killer cells of the invention have antitumor activity.

In this example, cancer cells per se were used as specific antigens in place of GRA for use in the process o:E the invention.
- Cancer cell-sensitized lymphocytes were obtained in the same manner as in Example 1 except that, in place of ~RA9 BT-l, Daudi~ KATO-III, or MKN-45 was used at a level of lx105 per laboratory dish.
~ ith these lymphocytes9 the cytotoxic activity was examined in the same manner as in Test Example 2 ~(a)). The results are shown in Table 9.
It c2n be seen from Table 9 that the above-prepared lymphocytes do not have any cytotoxic activity.
Table 9 Cells for Use in Sensiti-zation of Lymphocytes Target Cell BT-l Daudi KAT0-III MKN-45 BT-l Daud~
KATO-III

In the same manner as in TEST E~A~IPLE 2-(b), the cancer cell-killing activity of GRA-8-lC-T, GRA-3-A-K-T and GRA-3-C-K-T
obtained in EXAMPLE 4 was determined. The results obtained are shown in Table 10.
Table 10 Target % Cytotoxicit Cell GRA-8-K-T GRA-3-A-K-T GRA-3-C-K-T
KATO-III 8.0 5.0 5.0 BT-l 4.3 5.0 4.0 MKN-45 20 5.0 20 ~a) Cytotoxicity of each of killer cell preparations obtained in EXAMPLE 6 was determined by 51Cr release test (J. Immunol.
122, 2527-2533 (1979 ). That is, 50 ~Ci of radioactive 5lCr (Japan Isotope Association) was added to XATO-III (2x107) and the cells were incubated at 37C for l hour in RPMI-1640 medium and sufficiently washed by cen~rifugation to obtain 51Cr-labeled target cells. Killer cells ~effector cells) ~2x106~ were added to the target cells (lx105) (thus E/T =
20/1) and the mixture was incubated at 37C for 4 hours in RPMI-164Q medium. Supernatant was collected by centrifuga-tion and its radioactivity was determined by liquid scintilla-tion coun~eT.

~2~

The specific 51Cr Release (%) which corresponds to the cytolytic activity of effector cells was calculated according to the following equation.
Specific 51Cr Release (%) = ~Release in Test) - (Spontaneous Release) x 100 (Maximum Release) - (Spontaneous Release) ~The maximum release indicates the radioactivity when all the cells are lyse~), The results obtained are shown in Table 11.
Table 11 Specific 51Cr Killer Cell Release (%) GRA-l-K-T-l 13 GRA-l-K-T-2 25 GRA-l-K-T-3 22 GRA-l-K-T-4 20 GRA-l-K-T-5 22 GRA-l-K-T-6 25 GRA-l-K-T-7 27 GRA-l-K-T-8 32 From the results shown in Table 11 above, it can be seen that TCGF an~ FCS have no relation wi~h the induction of killer cells.
(b) Cytotoxicity of GRA-2-K-T obtained in EXAMPLE 3 was de~ermined by 51Cr release ~est in the same manner as in (a) above. Speci~ic 51Cr release of 14.3~ was observed on 51Cr-labeled KATO-III as target cell ~E/T = 20/1).

(a) Using ICATO-III (E/T = 20/1) as target cell cytotoxicity of killer cells obtained in EXAMPLE 7-(a) was determined in the same manner as in TEST EXAMPl,E 2-(b), The results obtained are shown in Table 12 below.
Table 12 Killer Cell % Cytotoxicity GRA-3-K-T-1 38.0 GRA-3-K-T-2 18.2 GRA-3-K-T-3 20.9 GRA-3-K-T-4 23.2 GRA-3-K-T-5 24.5 GRA-3-K-T-6 20.2 (b) Cytotoxicity of GRA-3-K-T-7 obtained in EXAMPLE 7-(b) was determined using 51Cr-KATO-III ~E/T = 20/1) as target cell in the same manner as in TEST EXAMPLE 5. Specific 51Cr release of the killer cell was found to be 25.5%.

Cytotoxici~y of ~he killer cells ob~ained in EXAMPLE 5 was determined by 51Cr release test in the same manner as in TEST EXAMPLE 5. The target cell used was 51Cr-labe]ed X5563 cell. As a control lymphocytes obtained in the same manner as in EXAMPLE 5 except that sensitization of spleen cells was carried out with lxlO5/well of mitomycin C-treated X5563 cells (5xlO6/mQ
of X5563 cells were treated with 50 ~g/mQ of Mitomycin C for 60 minutes) ins~ead of GRA-M-5 were used.

The results obtained are shown in Table 13 below.
Table 13 Specific 5lCr Release (%) E/T ratio Killer Cell 40:1 20:1 10:1 GRA-M-5-K-T-1 12.7 6.3 5.7 GRA-M-5-K-T-2 18.4 20.6 13.7 Control 0.0 0.0 0.0 TEST EXAMPLE 8 ~H-2 Assay) GRA-M-l, GRA-~ 3 and GRA-M-4 obtained in REFERENCE
EXAMPLF.2 above were serially diluted with PBS (0.85% NaCQ) to prepare samples.
Anti-H-2 serum rom National Institute of Genetic Research and the above sample were mixed and incubated at 4C
for 2 hours and a target cell corresponding to the anti-H-2 serum used was added thereto. Spleen cell or lymph node cell obtained -from B10 ~H-2b) and BlO-BR (H-2k) mice by conven-tional method were used as target cell. After washing the cells with PBS, complement (rabbit) was added to the cell and the cells were incubated a~ 37C for 1 hour and stained with 0.2% trypan blue-PBS to determine % cytotoxicity. The anti-H-2 serum was used in a maximum dilution such that it showed at least 95% cytotoxicity in the absence of GRA.
The blocking effect by GRA was determined for systems shown in Table 14 below.

- 4~ -able 14 GRA Anti-H-2 Serum, Concentration Target Cells .. . . .
GRA-M-l D-23 ~anti-H-2Kk), X80 BlOBR (H-2}C~
or k spleen cells D-32 (anti-~-2D ), X300 GRA-M-3 D-33 (anti-H-2Kb),X600 B10 (H-2b) or b spleen cells D-2 ~anti-H-2D ),X80 GRA-M-4 D-23 ,X80 BlO-BR ~h-2k) or lymph node cells D-32 ~X300 The results obtained are shown in Table 15.
Table 15 % Cytotoxicity . _ Anti-H-2 _ Dilution of Sample __ GRASerum XZ X4 X8 X16 X3Z X64 X128 X256 X512 0 *

Notes: GRA I GRA-M-l GRA II: GRA-M-3 GRA III: GRA-M 4 ~*t~ indicates % cytotoxicity when complement alone was used.

.... .. .. . . .

From the results shown in Table 15 a~ove it can be seen that GRA-M-l, GRA-M-3 and GRA-M-4 lack H-2.

C57BL/6 mouse was transplanted under S.C. with LLC (2x106) from the same strain and after 6 days 1 ng (protein) of GRA-.M-3 obtained in REFERENCE EXAMPLE 2-(d) was administered subcuta-neously. Thereafter administration was repeated for 4 days once a day at the same dosage. The day next the inal administ-r~-tion t~m)or cells were excised and weighed. As a control physiological saline administered animals were used. Each test group comprised 5 animals.
As a result, average tumor weight of the control group was found to be about 500 mg. In CRA-M-3 administered group 3 showed disappearance of tumor and two had average tumor weight of about 100 mg.

C57BL/6 mouse was immunized subcutaneously with 1 ng (protein) of GRA-M-3 obtained in REFERENCE EXAMPLE 2(d) once a day for 3 days and on day 5 spleen cells were collected from the animal to obtain effector cells. A mixture of the effector cells and Lewis lung carcinoma (LLC) as target cell in a ratio of E/T = 50:1 was prepared and a portion (lx105) thereo~ was *ransplanted to mouse of the same strain and Winn assay was performed (J. Immunol. _, p,228-239 (1961)).
The results obtained are shown in Table 16 below.

Table 16 Day 20 Effector Tumor Growth Rate ~%)_ Mortality/
Cells Day 15Day 17 Day 18 Day 19Day 20 Group A 5.75.5 5.7 3.1 1.4 0/10 B 21.439.5 37.1 55.4 76.8 4/10 C 39.365.1 61.7 9g.1 96,4 4/10 Notes: Group A represents spleen cells from GRA-M-3 immune mouse.
Group B represents spleen cells from normal mouse.
Group C represen-ts spleen cells ~rom mouse after 10 days from the transplantation of LLC (lx106).
Tumor Growth Rate was calculated according to the following equation:
Tumor Growth Rate ~%) = TA TN x 100 TN

wherein TA represents the thickness of the foot pad on the side where the tumor was transplanted and TN represents the thick-ness of the normal foot pad.

C3H/He mouse was immuni~ed with 4.5 ~g (protein) of GRA-M-4 obtained in REFERENCE EXAMPLE 2 ~d) and 0.1 m~:~of Freund's Complete A~juvant at the sacrococcygeal portion. After two weeks lymph node cells were collected by conventional me~hod and were used as responder cell for determining prolierative response by GRA-M-4.
For this purpose, responder cells (4x105) were incubated in RPMI-1640 medium containing 15~ FCS in the presence of GRA-M-4 for 5 days. During final 18 hours of the incubation period 1 ~Ci of 3H-thymidine ~3H-TdR) was added to the medium and its incorporation into the cells was counted.
The results obtained are shown in Table 17 below.
Table_17 Concentration 3H-TdR Incorporation GRA-M-4 ~ng/mQ)~mean cpm ~ S.E.) S.I.
Control 05,302 _ 1,761 0.57,903 + 1,290 1.5 110~076 ~ 936 1.9 Experiment 5 10,686 ~ 429 2.0 2010,615 + 1,270 2.0 408,565 ~ 1,419 1.6 Note: S.I. indicates stimulation index in terms of Experiment/Control.

Delayed type hypersensitivity ~DTH) response of C3H/He normal mouse, X5563 lmmune mouse and MH134 immwne mouse obtained in the same manner as in EXAMPLE 5, and GRA-M-4 immune mouse and GRA-M-5 immune mouse obtained ln the same manner as in TEST EXAMPLE 11 was determined by foot pad reaction (FPRj. That is9 GRA or MMC-treated tumor cells were challenged at the foot pad skin of the hind leg of the ~o~

animal and swelling of the foot pad 24 hours after the chalienge was determined. Degree of DTH response was calcu-lated by subtracting the swelling before challenge from that after challenge (lO 2 mm).
The results obtained are shown in Tables l8-22.
Table 18 Mean Foot Pad Increment (10_ mm) Challenge Normal MouseMH134 Immune Mouse _ . _ . _ _ .. ..
l 2.8 13.6 2 12.4 32.0 3 3.6 3.6 4 3.2 22.0 ~ 6.8 27.6 Notes: Group l; syngeneic normal spleen lxlO6/20 ~Q
medium (Hanks solution) l~ Group 2; MHl34 cell lxlO6/20 ~Q medium Group 3; medium 20 ~Q
Group 4; GRA-M-4, 0.8 ~g ~protein)/20 ~Q medium Group ~., " 0.4 ~g "
Table l9 Mean Foot Pad Increment ~lO 2 mm) Challenge Normal Mouse X5563 Immune Mouse MHl34 Immune Mouse l ~.4 4.3 l.l 2 0.9 - 24.3 3 2.0 16.9 Notes: ~oup l;~medium (Hanks solution) 20 ~Q
~ up 2; ~RA-M-4~ 4 ~g (protein)/20 ~Q medium Group 3; GRA M-5, Table 20 Mean Foot Pad Increment (10 2 mm) ChallengeNo~rmaI Mouse GRA-M-4, Immune Mouse 1 1.7 -0.3 2 5.1 24.6 Notes: Group l; medium (Hanks solution) 20 LQ
Group 2; GRA-M-4, 4 ~g (protein)/20 ~Q medium Table 21 Mean Foot Pad Increment (10 2 mm) ChallengeNormal Mouse GRA-M-4, Immune Mouse 1-1.8 0.6 26.3 20.0 36.8 6.3 Notes: Group l; medium ~Hanks solution) 20 ~Q
Group 2, GRA-M-4, 4 ~g (protein)/20 ~Q medium Group 3, 4 ~g (protein)/20 ~Q medium of fraction which passed through PNA-column at the time of GRA-M-4 (hereinafter "C.P.") Table 22 Mean Foot Pad Increment (10 2 mm) Challenge Normal_MouseGRA-M-4, Immune Mouse 1 2.4 -1.0 ~0 2 2.6 17.7 3 2.4 1.8 4 S.5 18.9 Notes: Group l; medium ~Hanks solution) 20 ~Q
Group 2; GRA-M-4, 3.8 ~g ~protein)/20 ~Q medium Group 3; 3.8 ~g (protein)/20 ~Q medium of "C.P."
above Group4; 3.8 ~ (protein) of GRA-M-4 and 3.8 ~g (protein)/20 ~Q medium of "C.P."
REFERENCE TEST
X5563 Immune mouse was obtained in the same ~anner as in EXAMPLE 5. Spleen cells from ~his immune mouse were used as effector cell and the effector cells (107) and target cells (X5563, 105~ were together transplanted to mouse of the same strain. Winn assay was performed in the same manner as in TEST EXA~PLE 10.
The results obtained are shown in Fig. 23, in which the - 15 abscissa indicates days and the coordinate shows mean tumor size (cmZ) ~ S.E. and various marks represent the following.
3 ~ O: Group in which effector cells were not added~
o -~o: Group in which non treated effector cells were ~added.
~ : Group in which effector cells treated with rabbit complement were added.
x x: Group in which effector cells treated with anti-Thy 1 (New England Nuclear Co.,U.S.A.) and rabbit complement were added.
0 ~ - : Group in which effector cells treated with anti-Lyt 1 (New England Nuclear Co.~ U.S.A) J~2~9~3~

and rabbit complement were added.
~: Group in which ef:fector cells treated with anti-Ly-t 2 (New England Nuclear Co.g U.S.A.) and rabbit complement were added.
From the results shown in Fig. 23 it can be seen that Lyt 1 type T-cells play an important role in the mecha-nism of _ vivo effector in tumor immunity.
Further, it is known that DTH response is mediated by Lyt-l T-cells~ (J. Exp. Med, 1~3 p,l534-39 (1976)).
While the in~ention has been described in detail and with reference to specific embodiment thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.

Claims (22)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A process for preparing a glyco-related antigen which is a cancer cell membrane component capable of combining with a lectin that can combine specifically with a terminal galactose or a terminal N-acetylgalactos-amine, comprising isolating a glyco-related antigen from cancer cell membrane components with said lectin.
2. A process as claimed in claim 1, wherein the process comprises isolating a glyco-related antigen from human cancer cell membrane component with the lectin.
3. A process as claimed in claim 2, wherein the lectin is one which can combine specifically with a terminal galactose.
4. A process as claimed in claim 2, wherein the lectin is one which can combine specifically with a terminal N-acetylgalactosamine.
5. A process for preparing a glyco-related antigen comprising isolating a glyco-related antigen from human cancer cell membrane component firstly with a first lectin which can combine specifically with a terminal galactose, and then with a second lectin which can combine specifically with a terminal N-acetylgalactosamine.
6. A process as claimed in claim 5 wherein the first lectin is peanut lectin and the second lectin is Dolichos bean agglutinin.
7. A process as claimed in claim 2, wherein the process comprises preparing cell membrane components from human cancer cells by homogenization or solubilization, treating the cell membrane components with the lectin to form a lectin-cell membrane component complex, collecting the resulting complex, separating the lectin from the complex and collecting a lectin-free cell membrane component.
8. A glyco-related antigen which is a cancer cell membrane component capable of combining with a lectin which can combine with a terminal galactose or a terminal N-acetylgalactosamine whenever prepared by a process as claimed in claim 1 or an obvious chemical equivalent there-of.
9. A glyco-related antigen as claimed in claim 8, whenever prepared by a process as claimed in claim 2 or an obvious chemical equivalent thereof.
10. A glyco-related antigen as claimed in claim 8, whenever prepared by a process as claimed in claim 3 or an obvious chemical equivalent thereof.
11. A glyco-related antigen as claimed in claim 8, whenever prepared by a process as claimed in claim 4 or an obvious chemical equivalent thereof.
12. A glyco-related antigen as defined in claim 8, whenever prepared by a process as claimed in claim 5 or an obvious chemical equivalent thereof.
13. A glyco-related antigen as defined in claim 8, whenever prepared by a process as claimed in claim 6 or an obvious chemical equivalent thereof.
14. A glyco-related antigen as defined in claim 8 whenever prepared by a process as claimed in claim 7 or an obvious chemical equivalent thereof.
15. A process as claimed in claim 3 wherein said lectin is selected from the group consisting of peanut lectin, Ricinus communis lectin and soybean lectin.
16. A glyco-related antigen as defined in claim 8 whenever prepared by a process as claimed in claim 15 or an obvious chemical equivalent thereof.
17. A process as claimed in claim 15 wherein said lectin is peanut lectin.
18. A glyco-related antigen as defined in claim 8 whenever prepared by a process as claimed in claim 17 or an obvious chemical equivalent thereof.
19. A process as claimed in claim 4 wherein the lectin is selected from the group consisting of Dolichos bean agglutinin, braid orange lectin Helix pomatia lectin, lima-bean lectin soybean lectin and Bauhinia bean lectin.
20. A glyco-related antigen as defined in claim 8 whenever prepared by a process as claimed in claim 19 or an obvious chemical equivalent thereof.
21. A process as claimed in claim 19 wherein said lectin is Dolichos bean agglutinin.
22. A glyco-related antigen as defined in claim 8 whenever prepared by a process as claimed in claim 21 or an obvious chemical equivalent thereof.
CA000406449A 1981-10-01 1982-06-30 Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes Expired CA1201988A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP156414/81 1981-10-01
JP56156413A JPS5857318A (en) 1981-10-01 1981-10-01 Production of lymphocytes inhibiting cancer cells
JP156413/81 1981-10-01
JP15641481A JPS5857321A (en) 1981-10-01 1981-10-01 Anticancer agent
JP158473/81 1981-10-05
JP158472/81 1981-10-05
JP56158472A JPS5859922A (en) 1981-10-05 1981-10-05 Cancer cell-disturbing lymphocyte
JP56158473A JPS5859923A (en) 1981-10-05 1981-10-05 Carcinostatic agent

Publications (1)

Publication Number Publication Date
CA1201988A true CA1201988A (en) 1986-03-18

Family

ID=27473414

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000406449A Expired CA1201988A (en) 1981-10-01 1982-06-30 Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes

Country Status (3)

Country Link
CA (1) CA1201988A (en)
ES (2) ES8402615A1 (en)
PH (1) PH22474A (en)

Also Published As

Publication number Publication date
PH22474A (en) 1988-09-12
ES514450A0 (en) 1984-03-01
ES523253A0 (en) 1984-10-01
ES8402615A1 (en) 1984-03-01
ES8407392A1 (en) 1984-10-01

Similar Documents

Publication Publication Date Title
Abrahamsen et al. In vitro mitogen stimulation of synovial fluid lymphocytes from rheumatoid arthritis and juvenile rheumatoid arthritis patients: dissociation between the response to antigens and polyclonal mitogens
JP2022000060A (en) Method for producing natural killer cell and composition for cancer treatment
EP0221748A2 (en) A process for the production of human antibodies
GB2106935A (en) Cancer cell-combatting lymphocytes process, for the production thereof, and anticancer agents containing said lymphocytes
AU632999B2 (en) Method and means for immuno-stimulating blood treatment with a mitogen
CA1201988A (en) Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes
WO1999051720A2 (en) Methods for production of therapeutic cytokines
FI80711C (en) Process for Preparing a Therapeutically Useful Thermally The Aturized, Glucoside Binding Antigen (GRA) Linked to Cancer Cells
NZ201112A (en) Preparation of a cancer-specific antigen and composition
Wilson et al. Specific (EMT6) and non-specific (WEHI-164) cytolytic activity by host cells infiltrating tumour spheroids
WO1990004633A1 (en) ACTIVATION AND GROWTH OF HUMAN TUMOR-INFILTRATING LYMPHOCYTES USING ANTIBODIES TO CD3 OR TcR
EP0157427A2 (en) Process for preparing glycosidic linkage related antigen
NZ214000A (en) Method of sensitising lymphocytes to cancer associated antigens
KR880001758B1 (en) Process for preparing lymp cell against cancer
Reymond et al. Transfer factor preparations: some physico-chemical and biological properties
US4772469A (en) Production of lymphoid tissue effector cells reactive against cancer cells by means of MER, and use thereof in cancer therapy
US7309501B2 (en) Conditioned media to inhibit growth of tumor cells
JPS591420A (en) Sugar chain-relating antigen and its preparation
NAKAJIMA et al. POLYSACCHARIDE, DMG, A DEGRADED D-MANNO-D-GLUCAN FROM MICROELLOBOSPORIA GRISEA CULTURE FLUID
NO850152L (en) PROCEDURE FOR MANUFACTURING HUMAN, EVEN CANCER REGULATORY FACTOR.
Walsh et al. Inhibition of the lymphocyte blastogenic response to antigen by serum-free culture supernatants of leukemic B cells
Orlando A study of the relationship between immunological enhancement and inhibition of hepatoma growth in syngeneic rats
Fritze et al. Conversion of human lymphocytes to antitumor immune reactivity by xenogeneic and allogeneic imune RNA detected by leukocyte-adherence inhibition tests
Binz et al. Studies on chemically induced tumors in rats: I. Heterogeneity of tumor cells and establishment of syngeneic, tumor-specific cytotoxic T cell clones
WO1991019509A1 (en) Protein a and polypeptide of its molecule for the treatment of tumors

Legal Events

Date Code Title Description
MKEX Expiry